Skip to main navigation Skip to search Skip to main content

Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data Basic Study

  • Ming Chin Yu
  • , Chao Wei Lee
  • , Yun Shien Lee
  • , Jang Hau Lian
  • , Chia Lung Tsai
  • , Yi Ping Liu
  • , Chun Hsing Wu
  • , Chi Neu Tsai*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • Xiamen Chang Gung Hospital
  • Chang Gung University
  • Ming Chuan University

Research output: Contribution to journalJournal Article peer-review

19 Scopus citations

Abstract

Aim To identify chromosomal copy number aberrations (CNAs) in early-stage hepatocellular carcinoma (HCC) and analyze whether they are correlated with patientOne hundred and twenty patients with early-stage HCC were enrolled in our study, with the collection of formalin fixed, paraffin-embedded (FFPE) specimens and clinicopathological data. Tumor areas were marked by certified pathologists on a hematoxylin and eosinstained slide, and cancer and adjacent non-cancerous tissues underwent extraction of DNA, which was analyzed with the Affymetrix OncoScan platform to assess CNAs and loss of heterozygosity (LOH). Ten individuals with nonmalignant disease were used as the control group. Another cohort consisting of 40 patients with stage ?/? HCC were enrolled to analyze gene expression and to correlate findings with the OncoScan data. RESULTS Copy number amplifications occurred at chromosomes 1q21.1-q44 and 8q12.3-24.3 and deletions were found at 4q13.1-q35.2, 8p 23.2-21.1, 16q23.3-24.3, and 17p13.3-12, while LOH commonly occurred at 1p32.3, 3p21.31, 8p23.2-21.1, 16q22.1-24.3, and 17p 13.3-11 in early-stage HCC. Using Cox regression analysis, we also found that a higher percentage of genome change (= 60%) was an independent factor for worse prognosis in early-stage HCC (P = 0.031). Among the 875 genes in the OncoScan GeneChip, six were independent predictors of worse disease-free survival, of which three were amplified (MYC, ELAC2, and SYK ) and three were deleted (GAK, MECOM, and WRN ). Further, patients with HCC who exhibited = 3 CNAs involving these six genes have worse outcomes compared to those who had < 3 CNAs (P < 0.001). Similarly, Asian patients with stage I HCC from The Cancer Genome Atlas harboring CNAs with these genes were also predicted to have poorer outcomes. CONCLUSION Patients with early-stage HCC and increased genome change or CNAs involving MYC, ELAC2, SYK, GAK, MECOM, or WRN are at risk for poorer outcome after resection.

Original languageEnglish
Pages (from-to)7818-7829
Number of pages12
JournalWorld Journal of Gastroenterology
Volume23
Issue number44
DOIs
StatePublished - 28 11 2017

Bibliographical note

Publisher Copyright:
© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Copy number aberration
  • Early-stage hepatocellular carcinoma
  • Molecular inversion probe
  • OncoScan
  • Prognosis

Fingerprint

Dive into the research topics of 'Prediction of early-stage hepatocellular carcinoma using OncoScan chromosomal copy number aberration data Basic Study'. Together they form a unique fingerprint.

Cite this